Aktis Oncology develops precision radiopharmaceuticals that utilize targeted alpha-emitting particles to treat solid tumors in cancers with limited treatment options. Their technology aims to enhance the efficacy of cancer therapies by delivering localized radiation directly to cancer cells, minimizing damage to surrounding healthy tissue.

This company develops small molecule antiviral drugs targeting infections caused by HPV, herpes viruses, HIV, and animal retroviruses. Their medicinal chemistry platform aims to create direct-acting antivirals, helping patients recover from viral diseases.

Arialys Therapeutics develops precision small‑molecule therapies that block pathogenic anti‑NMDA receptor autoantibodies while preserving normal receptor function. Its lead candidate, ART5803, is an oral drug that restores synaptic signaling in anti‑NMDA receptor encephalitis and related autoimmune neuropsychiatric disorders, offering a targeted alternative to broad immunosuppression.

The startup develops targeted therapies for patients with rare bone and connective tissue disorders, utilizing gene therapy techniques to prevent symptom onset and slow disease progression. By addressing the underlying genetic causes, the company enables patients to achieve improved health outcomes and quality of life.

AstronauTx is developing targeted therapeutics to restore the functionality of astrocytes, which are critical for maintaining brain health. This approach aims to correct disrupted brain physiology associated with neurodegenerative diseases, potentially improving patient outcomes.

Basecamp Bio develops cell and gene therapies using proprietary technologies such as gene editing, RNA engineering, and viral delivery systems to create effective treatments for various diseases. The company addresses the need for efficient manufacturing and development processes in the regenerative medicine sector, enabling faster access to life-saving therapies.

Crossbow Therapeutics develops T-Cell Receptor mimetic antibodies that precisely target tumor-specific peptides presented by Major Histocompatibility Complex (MHC), enhancing the efficacy of antibody therapies against cancer. Their technology addresses the challenge of reaching previously inaccessible cancer antigens, thereby broadening the therapeutic potential of immunotherapy for patients.

Cullinan Therapeutics develops targeted cancer therapeutics by identifying high-impact targets and selecting the optimal modality for treatment, utilizing a collaborative research model with academic and industry partners. The company aims to expedite the development of effective therapies for various cancer and autoimmune conditions, addressing the need for faster and more efficient drug programs.

Develops personalized cytokine-based therapies using a proprietary Diakine™ platform that combines anti-inflammatory and immune-stimulating cytokines to target cancer and inflammatory diseases. This approach enriches affected tissues with tailored cytokine combinations, aiming to control disease while minimizing toxic inflammation, offering a precision medicine solution for individual patient immune responses.

Dyne Therapeutics develops nucleic acid therapies using its proprietary FORCE™ platform to enhance muscle tissue delivery for patients with genetically driven muscle diseases. The company focuses on creating targeted treatments that aim to halt or reverse the progression of serious muscle disorders.

Entrada Therapeutics develops intracellular therapeutics using its proprietary EEV™ Platform to target previously inaccessible disease-causing mechanisms within cells. The company focuses on treating devastating diseases by creating potential therapies that span from discovery to clinical stages across various therapeutic areas.

Firefly Bio develops Degrader Antibody Conjugates (DACs) by integrating selective protein degraders with the capabilities of traditional ADCs. Their proprietary platform enables the highly specific delivery of these novel degraders directly to target tissues. This technology allows for the scalable access and utilization of new classes of ADC payloads.

Frontier Medicines utilizes a proprietary chemoproteomics platform combined with covalent chemistry and machine learning to identify and develop small-molecule therapies targeting previously undruggable disease-causing proteins. This approach enables the creation of precision medicines tailored to genetically-defined patient populations, enhancing treatment efficacy and patient outcomes.

NextPoint Therapeutics develops precision immuno-oncology therapies targeting the B7-H7/HHLA2 immune checkpoint to reactivate exhausted T and NK cells in solid tumors. This approach aims to provide effective treatment options for cancer patients who do not respond to existing PD-1/L1 inhibitors, enhancing therapeutic outcomes through biomarker-driven patient selection.

Orna Therapeutics develops fully engineered circular RNA (oRNA®) therapeutics and lipid nanoparticle (LNP) delivery systems to enable targeted treatment of diseases beyond the liver, including oncology and autoimmune disorders. Their technology addresses the limitations of traditional mRNA therapies by providing simplified production and enhanced protein expression, facilitating direct treatment options for conditions like sickle cell disease and beta-thalassemia.

Photys Therapeutics utilizes a proprietary platform of bifunctional small molecules to precisely control protein post-translational modifications, enhancing the phosphorylation of target proteins. This technology aims to restore protein function and amplify disease-fighting mechanisms, addressing the challenges of dysfunctional protein signaling in various diseases.

ReCode Therapeutics utilizes its Selective Organ Targeting (SORT) lipid nanoparticle platform to deliver mRNA and gene correction therapies directly to specific organs and tissues, bypassing the liver. The company focuses on developing treatments for genetically defined diseases, such as primary ciliary dyskinesia and cystic fibrosis, where no effective therapies currently exist.

Repare Therapeutics develops precision oncology drugs using its proprietary SNIPRx® platform to identify and target genetic alterations in tumor cells. The company focuses on creating synthetic lethality-based therapies to address cancers with significant unmet medical needs.

Reunion Neuroscience is developing RE104, a patented prodrug of 4-OH-DiPT that targets the serotonin 2A receptor to provide fast-acting, short-duration therapeutic effects for postpartum depression and other mental health disorders. The company aims to deliver effective treatment options for patients whose needs are unmet by current antidepressant therapies.

Trishula Therapeutics is developing TTX-030, a first-in-class anti-CD39 antibody that targets immune evasion mechanisms in the tumor microenvironment to enhance anti-tumor immune responses. This approach aims to prevent immune suppression caused by extracellular adenosine, thereby improving treatment outcomes for patients with metastatic pancreatic cancer and other solid tumors.

Umoja Biopharma develops an in vivo CAR T-cell gene therapy platform that reprograms the immune system to target solid tumors and hematological cancers resistant to current treatments. This approach aims to achieve durable remissions in patients by enhancing the body's natural ability to fight cancer.

Werewolf Therapeutics develops conditionally activated proinflammatory immune modulators, known as INDUKINE™ molecules, which are systemically administered in an inactive form and activated selectively within the tumor microenvironment. This approach targets the challenge of off-target effects in immunotherapy, enhancing the immune response against cancer while minimizing damage to healthy tissues.